var data={"title":"Fibrinolytic markers and cardiovascular risk","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Fibrinolytic markers and cardiovascular risk</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/contributors\" class=\"contributor contributor_credentials\">Robert S Rosenson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/contributors\" class=\"contributor contributor_credentials\">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/contributors\" class=\"contributor contributor_credentials\">Gordon M Saperia, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 02, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Elevated plasma concentrations of fibrinogen appear to be an independent predictor of initial and recurrent cardiovascular events. There is also increasing evidence that markers of impaired fibrinolysis are associated with both the development of coronary heart disease (CHD) and, in patients with CHD, an increased number of coronary events [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Atherosclerotic plaque rupture and erosions are recognized precipitants of thrombosis and lead to an acute ischemic syndrome [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/2-4\" class=\"abstract_t\">2-4</a>]. (See <a href=\"topic.htm?path=the-role-of-the-vulnerable-plaque-in-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;The role of the vulnerable plaque in acute coronary syndromes&quot;</a>.) </p><p>The thrombotic response to vascular injury is influenced by a variety of factors, including the thrombogenicity of the vessel wall [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/5\" class=\"abstract_t\">5</a>], platelet deposition, local blood flow (which is influenced by rheologic properties) [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/6,7\" class=\"abstract_t\">6,7</a>], and the effectiveness of protective fibrinolytic mechanisms [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/8-10\" class=\"abstract_t\">8-10</a>]. (See <a href=\"topic.htm?path=the-role-of-platelets-in-coronary-heart-disease\" class=\"medical medical_review\">&quot;The role of platelets in coronary heart disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">FIBRINOLYTIC ACTIVITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fibrinolytic activity is regulated by a balance between plasminogen activators, such as tissue-type plasminogen activator (t-PA), and inhibitors, such as plasminogen activator inhibitor type 1 (PAI-1), alpha-2-antiplasmin, and lipoprotein (a). PAI-1 is a major determinant of the resistance of platelet-rich arterial thrombi to thrombolysis as it binds to and inactivates both t-PA and urokinase-type plasminogen activator [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/11,12\" class=\"abstract_t\">11,12</a>]. (See <a href=\"topic.htm?path=thrombotic-and-hemorrhagic-disorders-due-to-abnormal-fibrinolysis\" class=\"medical medical_review\">&quot;Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis&quot;</a>.)</p><p>Decreased fibrinolytic activity is characterized by prolonged clot lysis times and elevated plasma concentrations of PAI-1 and t-PA antigen. Circulating t-PA antigen consists mainly of <span class=\"nowrap\">t-PA/PAI-1</span> complexes and lesser amounts of free t-PA. (See <a href=\"topic.htm?path=approach-to-the-adult-patient-with-a-bleeding-diathesis#H21\" class=\"medical medical_review\">&quot;Approach to the adult patient with a bleeding diathesis&quot;, section on 'Tests for fibrinolysis'</a>.)</p><p>Fibrinolytic activity demonstrates circadian variability. Among patients with stable coronary heart disease, PAI-1 activity peaks in the early morning while t-PA activity is at its nadir [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/13\" class=\"abstract_t\">13</a>]. This correlates with the circadian pattern of acute myocardial infarction. (See <a href=\"topic.htm?path=psychosocial-factors-in-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Psychosocial factors in acute myocardial infarction&quot;</a>.) Treatment with a beta blocker ameliorated this relatively prothrombotic state [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Plasminogen activator inhibitor type 1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PAI-1 is synthesized by endothelium and smooth muscle cells in normal and atherosclerotic arteries [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/8-10\" class=\"abstract_t\">8-10</a>]. PAI-1 synthesis is regulated by a number of cytokines, including platelet-derived growth factor, thrombin, interleukin-1, transforming growth factor-beta, basic fibroblast growth factor, angiotensin II, and endotoxin [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/14-18\" class=\"abstract_t\">14-18</a>]. Smooth muscle cells are major regulators of the fibrinolytic potential within the vessel wall; as a result, they influence the thrombotic response following endothelial disruption. </p><p>The human PAI-1 gene is located on chromosome 7 and polymorphism in the promoter region of the PAI-1 gene has been identified; it is characterized by a &quot;deletion&quot; allele with a sequence of four guanosines (4G) and an &quot;insertion&quot; allele with five guanosines (5G) [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/19\" class=\"abstract_t\">19</a>]. In one study, subjects who were homozygous for the 4G allele had levels of PAI-1 that were 30 percent higher than those who are homozygous for the 5G allele [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/20\" class=\"abstract_t\">20</a>]. Additionally, overexpression of the PAI-1 gene has been detected in the intima of human atherosclerosis arteries and specifically localized to smooth muscle cells and macrophages [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/8,10\" class=\"abstract_t\">8,10</a>].</p><p>The putative involvement of elevated PAI-1 activity in atherothrombosis may reflect two processes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased PAI-1 expression following plaque rupture or endothelial erosion may permit fibrin to persist on the surface of the injured vessel.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incorporation of fibrin into the vessel wall.</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">FIBRINOLYSIS AND CHD</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The relationship between fibrinolytic activity and CHD has been evaluated in patients with and without CHD. In patients with CHD, coronary atheromatous plaque burden, established with angiography, and smoking are associated with reduced acute local fibrinolytic activity of the heart due to both impaired acute release of t-PA and increased PAI-1 [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/21,22\" class=\"abstract_t\">21,22</a>]. In other reports, elevated PAI-1 <span class=\"nowrap\">and/or</span> prolonged clot lysis times appear to be predictive of unstable angina and myocardial infarction in patients with CHD [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/23-29\" class=\"abstract_t\">23-29</a>], restenosis following percutaneous angioplasty [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/30\" class=\"abstract_t\">30</a>], and stroke [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/31\" class=\"abstract_t\">31</a>]. In one study of 71 patients with myocardial infarction before age 45, for example, t-PA activity measured after venous occlusion was significantly reduced compared to 50 age- and sex-matched controls [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/27\" class=\"abstract_t\">27</a>]. The low t-PA activity was due to high plasma levels of PAI-1 and, to a lesser degree, impaired release of t-PA from the vessel wall.</p><p>The European Concerted Action on Thrombosis (ECAT) Angina Pectoris study evaluated 3043 patients with angina pectoris who were followed for two years [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/26\" class=\"abstract_t\">26</a>]. High levels of PAI-1 antigen, PAI-1 activity, t-PA antigen, and t-PA activity after venous occlusion were associated with an increased risk of coronary events [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/26\" class=\"abstract_t\">26</a>]. However, the associations of risk with PAI-1 antigen and PAI-1 activity risk disappeared after adjustment for parameters reflecting insulin resistance.</p><p>In patients admitted with acute coronary syndromes, systemic measurements may not correlate with endothelial fibrinolytic activity [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/29\" class=\"abstract_t\">29</a>]. In one study of patients with acute coronary syndromes, elevations in t-PA antigen and PAI-1 (compared to patients with stable angina) were seen at presentation and 10 days. In comparison, endothelial t-PA release was transiently reduced, returning to the values seen in patients with stable angina by 10 days. These observations suggest reduced endothelial fibrinolytic activity correlates more to intracoronary thrombus formation than to steady state concentrations of fibrinolytic markers.</p><p>For individuals with a family history of recurrent arterial thrombus or a patient with recurrent arterial thrombus in a minimal or moderately stenotic vessel, the clinician should consider an evaluation for prothrombotic risk. Elevated PAI-1 activity represents one source of impaired fibrinolysis that has some support from a genetic study. </p><p>Until further confirmation of PAI-1 polymorphisms has been established, we do not recommend routine analytical testing except for patients who have recurrent arterial thrombi.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Predicting the development of CHD</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In comparison to the preceding observations in patients with CHD, population-based studies have demonstrated an inconsistent relationship between fibrinolytic parameters and predicting the development of CHD. The range of conflicting data can be illustrated by the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low systemic fibrinolytic activity, as measured by the dilute clot lysis time, was a predictor of CHD [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/32\" class=\"abstract_t\">32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After adjustment for traditional risk factors, particularly HDL-cholesterol, tissue plasminogen activator (t-PA) antigen has not been a risk factor for future CHD or myocardial infarction [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/33,34\" class=\"abstract_t\">33,34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The association of circulating t-PA antigen with the risk of a first-ever nonfatal myocardial infarction or death from CHD was investigated in a 1925 cases and 3616-controls within the prospective population-based Reykjavik Study, which had a median follow-up of 19.4 years [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/22\" class=\"abstract_t\">22</a>]. For every one standard deviation increase, the age and sex-adjusted odds ratio for coronary heart disease was 1.25 (1.18, 1.33). However, after further adjustment for conventional cardiovascular risk factors, the odds ratio was 1.07 (0.99, 1.14) for t-PA antigen. In a meta-analysis that included the Reykjavik Study with 21 prospective studies (13 with t-PA antigen), adjusted risk ratio per one SD higher baseline level of t-PA antigen (5494 CHD cases) was 1.13 (1.06, 1.21). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are conflicting data as to whether PAI-1 activity [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/34,35\" class=\"abstract_t\">34,35</a>] or specific polymorphisms of the PAI-1 gene locus have predictive value [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lack of an important association between genetic variations of several fibrinolytic and coagulation proteins and the risk of a myocardial infarction was also shown by a pooled analysis of six studies involving 3395 patients and controls [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/38\" class=\"abstract_t\">38</a>]. There was no association with genetic variations of factor V Leiden or prothrombin mutations and only a weak association with fibrinogen or PAI-1 polymorphisms.</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Familial risk of CHD</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The association between PAI-1 activity and familial risk of premature CHD has been evaluated in several case-control series, but the findings have been inconsistent. In different studies, PAI-1 concentrations in offspring of patients with myocardial infarction have been higher than in controls without such a family history [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/39\" class=\"abstract_t\">39</a>] or similar to controls [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/40,41\" class=\"abstract_t\">40,41</a>].</p><p>In one series, a family history of CHD was associated with homozygosity for the 4G allele [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Relationship to cerebrovascular disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the relationship between the PAI-1 genotype and CHD is uncertain, there may be an association with the risk of cerebrovascular mortality in women. In one study of 12,239 women, aged 52 to 67, who were followed for 18 years, 4G4G homozygotes had a significantly reduced risk of cerebrovascular mortality when compared to 5G5G homozygotes (relative risk 0.4) [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/42\" class=\"abstract_t\">42</a>]. When compared to 5G5G homozygotes, the relative risk of cerebrovascular mortality in 4G5G heterozygotes was 0.7.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Relationship to hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertension is an established risk factor for cardiovascular disease, especially myocardial infarction and stroke, which are thrombotic complications. It is thus possible that hypertension may exert its effect, in part, through the promotion of a prothrombotic state. The association between impaired fibrinolysis and blood pressure was examined in the Framingham offspring population, which included 2652 men and women [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/43\" class=\"abstract_t\">43</a>]. In both sexes, the levels of PAI-1 and t-PA antigen were positively correlated with systolic and diastolic blood pressure (p&lt;0.001). Plasma viscosity was associated with systolic and diastolic blood pressure in women only. (See <a href=\"topic.htm?path=cardiovascular-risks-of-hypertension\" class=\"medical medical_review\">&quot;Cardiovascular risks of hypertension&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">FIBRINOLYSIS AND THE INSULIN RESISTANCE SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Insulin resistance has been associated with obesity, hypertension, dyslipidemia, and type 2 diabetes. This constellation of findings is called the insulin resistance syndrome, the metabolic syndrome, or syndrome X. Patients with insulin resistance are at increased risk of developing cardiovascular disease. (See <a href=\"topic.htm?path=the-metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x\" class=\"medical medical_review\">&quot;The metabolic syndrome (insulin resistance syndrome or syndrome X)&quot;</a>.)</p><p>Impaired fibrinolytic capacity is common in patients with the insulin resistance syndrome [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/44-51\" class=\"abstract_t\">44-51</a>]. The following reports illustrate the range of findings, and suggest that the increase in cardiovascular risk seen with insulin resistance is due at least in part to impaired fibrinolysis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an analysis from the Framingham Offspring Study, fasting insulin levels and levels of hemostatic factors were measured in 2962 patients (80 percent with normal glucose tolerance and 20 percent with glucose intolerance or diabetes). Levels of PAI-1 and tPA antigen were significantly higher among patients with glucose intolerance than among those with normal glucose tolerance. In both groups of patients, levels of PAI-1 and tPA antigen increased significantly across quintiles of fasting insulin concentration.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The relationship between fibrinolytic markers and the insulin resistance syndrome was also examined in 1484 patients with angina pectoris as part of the ECAT Angina Pectoris study [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/45\" class=\"abstract_t\">45</a>]. Fasting serum insulin correlated with PAI-1 activity, PAI-1 antigen, and t-PA antigen. This correlation decreased after adjustment for other elements of the insulin resistance syndrome (primarily body mass index and triglycerides).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a cross-sectional study of 1276 patients of South Asian, Chinese, European, and Native Indian ancestry, those with the metabolic syndrome had significantly higher levels of PAI-1 (24.2 versus 14.6 <span class=\"nowrap\">U/mL),</span> significantly more atherosclerosis (maximum intimal medial thickness 0.78 versus 0.74) and a higher prevalence of cardiovascular disease (17 versus 7 percent) [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/46\" class=\"abstract_t\">46</a>]. Patients with the metabolic syndrome had an increased risk of cardiovascular disease, which remained significant after adjustment for carotid intimal-medial thickness, age, sex, and smoking. However, the increase in risk was no longer significant after adjustment for PAI-1 levels.</p><p/><p>The individual components of the insulin resistance syndrome increase the expression of PAI-1:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Insulin and insulin-like growth factor-1 (IGF-1) increase PAI-1 mRNA levels [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/52,53\" class=\"abstract_t\">52,53</a>]. In addition, glucose, with or without insulin, increases PAI-1 mRNA and PAI-1 secretion in endothelial cells, suggesting that the increase in PAI-1 associated with type 2 diabetes may be partly due to hyperglycemia [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/54\" class=\"abstract_t\">54</a>]. However, a major role of hyperglycemia is unlikely since PAI-1 levels are normal in patients with type 1 diabetes [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/55,56\" class=\"abstract_t\">55,56</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obesity can also induce expression and secretion of PAI-1. Obese patients have significantly higher adipose tissue PAI-1 mRNA levels and plasma PAI-1 protein levels than nonobese patients [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/57\" class=\"abstract_t\">57</a>]. Selected cytokines expressed in adipose tissue increase the production of PAI-1, including transforming growth factor beta 1 (TGF beta 1), tumor necrosis factor alpha (TNF alpha), and interleukin 1 beta (IL 1 beta) [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/14,58\" class=\"abstract_t\">14,58</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertriglyceridemia reflects the accumulation of triglyceride-rich lipoproteins, including VLDL, in plasma. VLDL induces overexpression of PAI-1 mRNA [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/53\" class=\"abstract_t\">53</a>] and increases PAI-1 release by endothelial and HepG2 cells [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/59,60\" class=\"abstract_t\">59,60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obese patients have increased levels of angiotensinogen compared to nonobese patients [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/61\" class=\"abstract_t\">61</a>] and adipocytes from obese individuals secrete more angiotensinogen [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/62\" class=\"abstract_t\">62</a>]. Several metabolites of angiotensinogen (angiotensin II, III and IV) induce PAI-1 expression and release via the AT-1 receptor on adipocytes [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">FIBRINOLYSIS AND HYPERLIPOPROTEINEMIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An association has been noted between impaired fibrinolysis and certain lipoproteins.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Triglycerides and VLDL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Plasma triglycerides and very low density lipoprotein (VLDL) have been positively correlated with PAI-1 antigen, PAI-1 activity, and t-PA antigen, and negatively correlated with t-PA activity activation measured after venous occlusion [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/60,64\" class=\"abstract_t\">60,64</a>]. In one report, lowering plasma triglycerides by 20 percent or more with a low-carbohydrate diet in hypertriglyceridemic subjects was associated with a 40 percent reduction in PAI-1 antigen levels (p&lt;0.05) [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/60\" class=\"abstract_t\">60</a>].</p><p>The latter observation suggests that triglycerides or VLDL might increase PAI-1 release. In vitro studies are compatible with this hypothesis as VLDL causes a dose-dependent release of PAI-1 from endothelial and hepatic (HepG2) cells [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/59,60\" class=\"abstract_t\">59,60</a>]. This effect is mediated by an interaction with the LDL receptor that involves overexpression of the stable 2.2 kb PAI-1 mRNA with a minor effect on the 3.2 kb PAI-1 mRNA transcript [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/53\" class=\"abstract_t\">53</a>]. VLDL induces transcription of the VLDL response element (VLDLRE) located at residues -672 to -657 in the promoter region of the human PAI-1 gene; this activity is influenced by the <span class=\"nowrap\">4G/5G</span> polymorphism, which is adjacent to the binding site of the VLDLRE [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/65\" class=\"abstract_t\">65</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Low density lipoprotein</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The release of t-PA from endothelial cells is suppressed by LDL, Lp(a), and HDL in a dose-dependent manner [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/66\" class=\"abstract_t\">66</a>]. In addition, LDL and acetylated LDL can stimulate PAI-1 release, an effect that is not dependent upon an interaction with the LDL receptor [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/67\" class=\"abstract_t\">67</a>]. These actions of LDL may partly explain the finding in an epidemiologic study that hyperlipidemia is associated with an imbalance of coagulation over fibrinolysis, as measured by molecular markers [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Lipoprotein(a)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lp(a) may interfere with fibrinolysis by competing with plasminogen binding to plasminogen receptors, fibrinogen, fibrin, and t-PA [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/69-71\" class=\"abstract_t\">69-71</a>]. The interference with plasminogen binding is mediated by the fourth kringle of the apoprotein (a) component of Lp(a), which is homologous with the fibrin-binding domain of plasminogen [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/72\" class=\"abstract_t\">72</a>]. Other antifibrinolytic properties of Lp(a) include impaired activation of plasminogen by t-PA [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/71\" class=\"abstract_t\">71</a>] and induction of PAI-1 synthesis [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/73\" class=\"abstract_t\">73</a>]. However, these in vitro findings have yet to be tested in observational and interventional studies. (See <a href=\"topic.htm?path=lipoprotein-a-and-cardiovascular-disease\" class=\"medical medical_review\">&quot;Lipoprotein(a) and cardiovascular disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">THERAPEUTIC APPROACHES TO IMPAIRED FIBRINOLYSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of therapies for patients at increased risk for CHD are also effective in those with impaired fibrinolysis.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Diet</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alterations in diet can improve fibrinolytic activity. PAI-1 levels can be reduced by a low carbohydrate diet in hypertriglyceridemic subjects [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/60\" class=\"abstract_t\">60</a>] and by a hypocaloric diet in overweight individuals [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/74-76\" class=\"abstract_t\">74-76</a>]. As an example, the effect of diet, with or without exercise, on fibrinolysis was evaluated in 121 healthy overweight postmenopausal women who were randomized to 12 weeks of a reduced caloric diet only, a reduced caloric diet plus exercise (aerobic and anaerobic for 1 to 1.5 hours three times per week), or no intervention [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/76\" class=\"abstract_t\">76</a>]. At baseline, PAI-1 activity, PAI-1 antigen, and t-PA antigen correlated with waist-to-hip ratio, <span class=\"nowrap\">abdominal/total</span> fat tissue mass, systolic blood pressure, fasting blood glucose, and serum triglycerides. After 12 weeks, diet alone lowered PAI-1 activity by 46 percent, PAI-1 antigen by 36 percent, and t-PA antigen by 29 percent compared with no intervention. Exercise conferred no additional benefit. At six months, there was no significant change in fibrinolysis despite maintenance of an 8 kg weight loss.</p><p>Thus, fibrinolysis can be transiently improved by an energy-restrictive diet, but cannot be maintained by continued weight loss. Neither PAI-1 nor t-PA activity appear to be affected by fish oils or polyunsaturated corn oil [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/77\" class=\"abstract_t\">77</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Alcohol intake</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fibrinolysis can be improved by moderate alcohol intake (three to seven drinks per week), which may contribute to the cardiovascular benefit of alcohol. The Framingham Offspring study found that moderate alcohol intake was associated with lower levels of fibrinogen, von Willebrand factor, plasma viscosity, and factor VII [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/78\" class=\"abstract_t\">78</a>]. In contrast, a higher intake of alcohol (7 to 21 drinks per week) was associated with impaired fibrinolytic potential. There was no relationship between these effects and beverage type [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/79\" class=\"abstract_t\">79</a>]. (See <a href=\"topic.htm?path=cardiovascular-benefits-and-risks-of-moderate-alcohol-consumption#H19\" class=\"medical medical_review\">&quot;Cardiovascular benefits and risks of moderate alcohol consumption&quot;, section on 'Antithrombotic effects'</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Aerobic exercise</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cross-sectional studies have shown that PAI-1 levels are inversely correlated with physical activity [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/80\" class=\"abstract_t\">80</a>]. Furthermore, physical training improves fibrinolysis by lowering PAI-1 [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/81-83\" class=\"abstract_t\">81-83</a>]; the benefit of exercise is seen primarily in homozygotes for the 4G allele who have elevated PAI-1 levels [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/84,85\" class=\"abstract_t\">84,85</a>].</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Metformin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients (usually obese) with type 2 diabetes, <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a> improves insulin resistance and lowers the blood glucose and plasma insulin and PAI-1 concentrations [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/86-88\" class=\"abstract_t\">86-88</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Lipid-lowering drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several studies have evaluated the effect of HMG-CoA reductase inhibitors (statins) and the fibric acid derivatives on fibrinolytic activity. Statins have a significant beneficial effect on fibrinolytic parameters [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/89\" class=\"abstract_t\">89</a>]. <a href=\"topic.htm?path=pravastatin-drug-information\" class=\"drug drug_general\">Pravastatin</a>, for example, reduces PAI-1 antigen levels by 26 to 56 percent [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/90,91\" class=\"abstract_t\">90,91</a>]. Similar beneficial effects have been reported with <a href=\"topic.htm?path=lovastatin-drug-information\" class=\"drug drug_general\">lovastatin</a>, <a href=\"topic.htm?path=atorvastatin-drug-information\" class=\"drug drug_general\">atorvastatin</a>, <a href=\"topic.htm?path=simvastatin-drug-information\" class=\"drug drug_general\">simvastatin</a>, and <a href=\"topic.htm?path=fluvastatin-drug-information\" class=\"drug drug_general\">fluvastatin</a> [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/92-95\" class=\"abstract_t\">92-95</a>].</p><p>The fibric acid derivatives also have favorable effects on fibrinolytic markers. In one report, for example, 20 patients with primary (type IV) hypertriglyceridemia were randomized to therapy with <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a> (600 mg BID) or placebo [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/96\" class=\"abstract_t\">96</a>]. At 12 weeks, gemfibrozil, compared to placebo, significantly reduced PAI-1 activity, and enhanced t-PA antigen release after venous occlusion. The improvement in fibrinolysis correlated with the magnitude of triglyceride lowering. In another study of 21 hyperlipidemic cardiac transplant recipients, <a href=\"topic.htm?path=bezafibrate-united-states-not-available-drug-information\" class=\"drug drug_general\">bezafibrate</a> lowered PAI-1 concentrations by 12 percent [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/97\" class=\"abstract_t\">97</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">ACE inhibitors/angiotensin receptor blockers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Angiotensin II can influence plasma fibrinolytic properties by inducing the release of PAI-1 [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/98\" class=\"abstract_t\">98</a>]. The administration of angiotensin converting enzyme (ACE) inhibitors in patients with hypertension and diabetes or after a myocardial infarction reduces PAI-1 concentrations; this effect is independent of blood pressure reduction [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/99,100\" class=\"abstract_t\">99,100</a>]. ACE inhibitors are more effective in those who are homozygous for the 4G allele [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/101\" class=\"abstract_t\">101</a>]. Whether this contributes to the beneficial effect of these drugs in these settings is not known. Studies in patients with heart failure suggest that the angiotensin II receptor antagonist <a href=\"topic.htm?path=losartan-drug-information\" class=\"drug drug_general\">losartan</a> has a similar effect on PAI-1 and that both classes of drugs may increase t-PA activity [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/102\" class=\"abstract_t\">102</a>]. (See <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Hormone replacement therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The association between the use of estrogen replacement therapy (ERT) and fibrinolytic variables in postmenopausal women has been examined in two cross-sectional studies [<a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/103,104\" class=\"abstract_t\">103,104</a>]. However, the clinical significance of any changes that might occur is not certain. The Women's Health Initiative, mostly of primary prevention, and the HERS trials of secondary prevention showed that estrogen-progestin replacement had no cardioprotective effect and may have produced harm. (See <a href=\"topic.htm?path=menopausal-hormone-therapy-and-cardiovascular-risk\" class=\"medical medical_review\">&quot;Menopausal hormone therapy and cardiovascular risk&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Impaired fibrinolysis is associated with an increased incidence of coronary events in patients with acute coronary syndromes. The pathophysiologic role of impaired fibrinolytic mechanisms is uncertain since the increase in risk appears to be confined to the acute phase. Population-based studies do not support impaired fibrinolytic parameters as independent predictors for the development CHD although genetic analyses of the PAI-1 <span class=\"nowrap\">4G/5G</span> polymorphism may clarify these issues in future prospective studies.</p><p>Impaired fibrinolysis is present in patients with type 2 diabetes mellitus, hyperlipidemia (especially hypertriglyceridemia), physical inactivity, and post-menopausal women. Therapies shown to improve fibrinolysis are those of benefit for CHD risk in general and include dietary modification, acute weight loss, <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a> in type 2 diabetics, LDL-cholesterol lowering with a statin, and triglyceride lowering with <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a>.</p><p>Until the role of PAI-1 <span class=\"nowrap\">4G/5G</span> polymorphisms and other genetic determinants of fibrinolysis are clarified, measurement of fibrinolytic parameters as part of the risk evaluation for coronary heart disease is <strong>not</strong> warranted.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/1\" class=\"nounderline abstract_t\">Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/2\" class=\"nounderline abstract_t\">Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94:2013.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/3\" class=\"nounderline abstract_t\">Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93:1354.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/4\" class=\"nounderline abstract_t\">Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/5\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/6\" class=\"nounderline abstract_t\">Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992; 94:93.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/7\" class=\"nounderline abstract_t\">Rosenson, RS . Viscosity and ischemic heart disease. J Vasc Med Biol 1993; 4:206.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/8\" class=\"nounderline abstract_t\">Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89:6998.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/9\" class=\"nounderline abstract_t\">Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/10\" class=\"nounderline abstract_t\">Chomiki N, Henry M, Alessi MC, et al. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72:44.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/11\" class=\"nounderline abstract_t\">Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99:3050.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/12\" class=\"nounderline abstract_t\">Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69:381.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/13\" class=\"nounderline abstract_t\">Sayer JW, Gutteridge C, Syndercombe-Court D, et al. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1998; 32:1962.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/14\" class=\"nounderline abstract_t\">Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88:1346.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/15\" class=\"nounderline abstract_t\">Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105:957.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/16\" class=\"nounderline abstract_t\">Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266:9419.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/17\" class=\"nounderline abstract_t\">Wojta J, Gallicchio M, Zoellner H, et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 1993; 70:469.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/18\" class=\"nounderline abstract_t\">Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95:995.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/19\" class=\"nounderline abstract_t\">Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995; 74:837.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/20\" class=\"nounderline abstract_t\">Humphries SE, Panahloo A, Montgomery HE, et al. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997; 78:457.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/21\" class=\"nounderline abstract_t\">Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001; 103:1936.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/22\" class=\"nounderline abstract_t\">Willeit P, Thompson A, Aspelund T, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One 2013; 8:e55175.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/23\" class=\"nounderline abstract_t\">Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/24\" class=\"nounderline abstract_t\">Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88:2030.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/25\" class=\"nounderline abstract_t\">Zalewski A, Shi Y, Nardone D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates. Circulation 1991; 83:1685.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/26\" class=\"nounderline abstract_t\">Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94:2057.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/27\" class=\"nounderline abstract_t\">Hamsten A, Wiman B, de Faire U, Blomb&auml;ck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/28\" class=\"nounderline abstract_t\">Hoffmeister HM, Jur M, Wendel HP, et al. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995; 91:2520.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/29\" class=\"nounderline abstract_t\">Hoffmeister HM, Jur M, Ruf-Lehmann M, et al. Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 1998; 31:547.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/30\" class=\"nounderline abstract_t\">Huber K, J&ouml;rg M, Probst P, et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67:209.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/31\" class=\"nounderline abstract_t\">Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14:1741.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/32\" class=\"nounderline abstract_t\">Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/33\" class=\"nounderline abstract_t\">Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/34\" class=\"nounderline abstract_t\">Lowe GD, Yarnell JW, Sweetnam PM, et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79:129.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/35\" class=\"nounderline abstract_t\">Scarabin PY, Aillaud MF, Amouyel P, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80:749.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/36\" class=\"nounderline abstract_t\">Gardemann A, Lohre J, Katz N, et al. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999; 82:1121.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/37\" class=\"nounderline abstract_t\">Anderson JL, Muhlestein JB, Habashi J, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 1999; 34:1778.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/38\" class=\"nounderline abstract_t\">Boekholdt SM, Bijsterveld NR, Moons AH, et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104:3063.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/39\" class=\"nounderline abstract_t\">Rallidis LS, Megalou AA, Papageorgakis NH, et al. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction. Thromb Haemost 1996; 76:417.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/40\" class=\"nounderline abstract_t\">Bara L, Nicaud V, Tiret L, et al. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring--the EARS study. European Atherosclerosis Research Study Group. Thromb Haemost 1994; 71:434.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/41\" class=\"nounderline abstract_t\">Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:152.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/42\" class=\"nounderline abstract_t\">Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101:67.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/43\" class=\"nounderline abstract_t\">Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101:264.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/44\" class=\"nounderline abstract_t\">Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283:221.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/45\" class=\"nounderline abstract_t\">Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13:1865.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/46\" class=\"nounderline abstract_t\">Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108:420.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/47\" class=\"nounderline abstract_t\">Eliasson M, Asplund K, Evrin PE, et al. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism 1994; 43:1579.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/48\" class=\"nounderline abstract_t\">Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152:897.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/49\" class=\"nounderline abstract_t\">Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28:371.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/50\" class=\"nounderline abstract_t\">McGill JB, Schneider DJ, Arfken CL, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43:104.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/51\" class=\"nounderline abstract_t\">Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33:431.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/52\" class=\"nounderline abstract_t\">Fattal PG, Schneider DJ, Sobel BE, Billadello JJ. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992; 267:12412.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/53\" class=\"nounderline abstract_t\">Sironi L, Mussoni L, Prati L, et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996; 16:89.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/54\" class=\"nounderline abstract_t\">Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13:1822.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/55\" class=\"nounderline abstract_t\">Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8:68.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/56\" class=\"nounderline abstract_t\">Mahmoud R, Raccah D, Alessi MC, et al. Fibrinolysis in insulin-dependent diabetic patients with or without nephropathy. Fibrinolysis 1992; 6:105.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/57\" class=\"nounderline abstract_t\">Eriksson P, Reynisdottir S, L&ouml;nnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41:65.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/58\" class=\"nounderline abstract_t\">Birgel M, Gottschling-Zeller H, R&ouml;hrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20:1682.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/59\" class=\"nounderline abstract_t\">Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/60\" class=\"nounderline abstract_t\">Mussoni L, Mannucci L, Sirtori M, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12:19.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/61\" class=\"nounderline abstract_t\">Umemura S, Nyui N, Tamura K, et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997; 10:629.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/62\" class=\"nounderline abstract_t\">Engeli S, Gorzelniak K, Kreutz R, et al. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17:555.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/63\" class=\"nounderline abstract_t\">Skurk T, Lee YM, R&ouml;hrig K, Hauner H. Effect of angiotensin peptides on PAI-1 expression and production in human adipocytes. Horm Metab Res 2001; 33:196.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/64\" class=\"nounderline abstract_t\">Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140:271.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/65\" class=\"nounderline abstract_t\">Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18:20.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/66\" class=\"nounderline abstract_t\">Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14:438.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/67\" class=\"nounderline abstract_t\">Tremoli E, Camera M, Maderna P, et al. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993; 13:338.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/68\" class=\"nounderline abstract_t\">Lowe GD, Wood DA, Douglas JT, et al. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost 1991; 65:339.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/69\" class=\"nounderline abstract_t\">Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry 1991; 30:6671.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/70\" class=\"nounderline abstract_t\">Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 1989; 86:3847.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/71\" class=\"nounderline abstract_t\">Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:240.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/72\" class=\"nounderline abstract_t\">McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/73\" class=\"nounderline abstract_t\">Etingin OR, Hajjar DP, Hajjar KA, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266:2459.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/74\" class=\"nounderline abstract_t\">Mehrabian M, Peter JB, Barnard RJ, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990; 84:25.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/75\" class=\"nounderline abstract_t\">Huisveld IA, Leen R, VdKooy K, et al. Body composition and weight reduction in relation to antigen and activity of plasminogen activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis 1990; 4:184.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/76\" class=\"nounderline abstract_t\">Svendsen OL, Hassager C, Christiansen C, et al. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 1996; 16:381.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/77\" class=\"nounderline abstract_t\">Toft I, B&oslash;naa KH, Ingebretsen OC, et al. Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol 1997; 17:814.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/78\" class=\"nounderline abstract_t\">Mukamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation 2001; 104:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/79\" class=\"nounderline abstract_t\">Howard BJ, Hurtig-Wennl&ouml;f A, Olsson LA, et al. Self-Reported Sitting Time, Physical Activity and Fibrinolytic and Other Novel Cardio-Metabolic Biomarkers in Active Swedish Seniors. PLoS One 2016; 11:e0163409.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/80\" class=\"nounderline abstract_t\">Shaukat N, Douglas JT, Bennet JL, de Bono DP. Can physical activity explain the differences in insulin levels and fibrinolytic activity between young Indo-origin and European relative of patients with coronary heart disease. Fibrinolysis 1995; 9:55.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/81\" class=\"nounderline abstract_t\">Speiser W, Langer W, Pschaick A, et al. Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb Res 1988; 51:543.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/82\" class=\"nounderline abstract_t\">Estell&eacute;s A, Aznar J, Tormo G, et al. Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 1989; 55:203.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/83\" class=\"nounderline abstract_t\">Gris JC, Schved JF, Feugeas O, et al. Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men. Thromb Haemost 1990; 64:516.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/84\" class=\"nounderline abstract_t\">V&auml;is&auml;nen SB, Humphries SE, Luong LA, et al. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. Thromb Haemost 1999; 82:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/85\" class=\"nounderline abstract_t\">Lind L, Carlsson AC, Siegbahn A, et al. Impact of physical activity on cardiovascular status in obesity. Eur J Clin Invest 2017; 47:167.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/86\" class=\"nounderline abstract_t\">Vague P, Juhan-Vague I, Alessi MC, et al. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57:326.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/87\" class=\"nounderline abstract_t\">Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997; 46:454.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/88\" class=\"nounderline abstract_t\">Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991; 8:361.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/89\" class=\"nounderline abstract_t\">Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/90\" class=\"nounderline abstract_t\">Avellone G, Di Garbo V, Panno AV, et al. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol 1988; 7:270.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/91\" class=\"nounderline abstract_t\">Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14:829.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/92\" class=\"nounderline abstract_t\">Isaacsohn JL, Setaro JF, Nicholas C, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994; 74:735.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/93\" class=\"nounderline abstract_t\">Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79:1475.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/94\" class=\"nounderline abstract_t\">Mitropoulos KA, Armitage JM, Collins R, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997; 18:235.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/95\" class=\"nounderline abstract_t\">Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79:84.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/96\" class=\"nounderline abstract_t\">Avellone G, Di Garbo V, Cordova R, et al. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coagul Fibrinolysis 1995; 6:543.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/97\" class=\"nounderline abstract_t\">Zambrana JL, Velasco F, Castro P, et al. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Am J Cardiol 1997; 80:836.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/98\" class=\"nounderline abstract_t\">Vaughan DE. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition. Clin Cardiol 1997; 20:II.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/99\" class=\"nounderline abstract_t\">Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997; 96:442.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/100\" class=\"nounderline abstract_t\">Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105:457.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/101\" class=\"nounderline abstract_t\">Brown NJ, Abbas A, Byrne D, et al. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002; 105:304.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/102\" class=\"nounderline abstract_t\">Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99:2983.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/103\" class=\"nounderline abstract_t\">Shahar E, Folsom AR, Salomaa VV, et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1996; 93:1970.</a></li><li><a href=\"https://www.uptodate.com/contents/fibrinolytic-markers-and-cardiovascular-risk/abstract/104\" class=\"nounderline abstract_t\">Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91:1952.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1509 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">FIBRINOLYTIC ACTIVITY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Plasminogen activator inhibitor type 1</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">FIBRINOLYSIS AND CHD</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Predicting the development of CHD</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Familial risk of CHD</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Relationship to cerebrovascular disease</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Relationship to hypertension</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">FIBRINOLYSIS AND THE INSULIN RESISTANCE SYNDROME</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">FIBRINOLYSIS AND HYPERLIPOPROTEINEMIA</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Triglycerides and VLDL</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Low density lipoprotein</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Lipoprotein(a)</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">THERAPEUTIC APPROACHES TO IMPAIRED FIBRINOLYSIS</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">Diet</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Alcohol intake</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Aerobic exercise</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Metformin</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Lipid-lowering drugs</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">ACE inhibitors/angiotensin receptor blockers</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Hormone replacement therapy</a></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action\" class=\"medical medical_review\">Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-patient-with-a-bleeding-diathesis\" class=\"medical medical_review\">Approach to the adult patient with a bleeding diathesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiovascular-benefits-and-risks-of-moderate-alcohol-consumption\" class=\"medical medical_review\">Cardiovascular benefits and risks of moderate alcohol consumption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiovascular-risks-of-hypertension\" class=\"medical medical_review\">Cardiovascular risks of hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipoprotein-a-and-cardiovascular-disease\" class=\"medical medical_review\">Lipoprotein(a) and cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=menopausal-hormone-therapy-and-cardiovascular-risk\" class=\"medical medical_review\">Menopausal hormone therapy and cardiovascular risk</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=psychosocial-factors-in-acute-myocardial-infarction\" class=\"medical medical_review\">Psychosocial factors in acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x\" class=\"medical medical_review\">The metabolic syndrome (insulin resistance syndrome or syndrome X)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-role-of-platelets-in-coronary-heart-disease\" class=\"medical medical_review\">The role of platelets in coronary heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-role-of-the-vulnerable-plaque-in-acute-coronary-syndromes\" class=\"medical medical_review\">The role of the vulnerable plaque in acute coronary syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thrombotic-and-hemorrhagic-disorders-due-to-abnormal-fibrinolysis\" class=\"medical medical_review\">Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis</a></li></ul></div></div>","javascript":null}